DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00302341
Recruitment Status : Terminated (FDA Clinical Hold as of 12/21/07 due to safety concerns)
First Posted : March 14, 2006
Last Update Posted : March 7, 2013
Information provided by (Responsible Party):
Immtech Pharmaceuticals, Inc

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2008
  Actual Study Completion Date : December 2008